Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer

NCT07017673 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

34

Enrollment

OTHER

Sponsor class

Conditions

TNBC
TNBC - Triple-Negative Breast Cancer
Early Stage Triple-Negative Breast Carcinoma

Interventions

DRUG: Ivonescimab
DRUG: Carboplatin
DRUG: Docetaxel

Sponsor

Cedars-Sinai Medical Center

Collaborators

[object Object]